keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer screening

keyword
https://www.readbyqxmd.com/read/28527899/egfr-mutation-analysis-for-prospective-patient-selection-in-two-phase-ii-registration-studies-of-osimertinib
#1
Suzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, Kenneth S Thress, Karen Yu, Rachel Hodge, Susie Weston, Simon Dearden, Sabina Patel, Mireille Cantarini, Frances A Shepherd
INTRODUCTION: Osimertinib is an oral, CNS active, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of EGFR T790M-positive advanced non-small cell lung cancer (NSCLC). Here we evaluate EGFR mutation frequencies in two Phase II studies of osimertinib (AURA extension and AURA2). METHODS: Patients with EGFR mutation-positive advanced NSCLC provided tumor samples following progression on their latest line of therapy for mandatory central T790M testing for study selection criteria...
May 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28525370/mathematical-modelling-for-phase-i-cancer-trials-a-study-of-metronomic-vinorelbine-for-advanced-non-small-cell-lung-cancer-nsclc-and-mesothelioma-patients
#2
Fabrice Barlesi, Diane-Charlotte Imbs, Pascale Tomasini, Laurent Greillier, Melissa Galloux, Albane Testot-Ferry, Mélanie Garcia, Xavier Elharrar, Annick Pelletier, Nicolas André, Céline Mascaux, Bruno Lacarelle, Raouf El Cheikh, Raphaël Serre, Joseph Ciccolini, Dominique Barbolosi
INTRODUCTION: Using mathematical modelling allows to select a treatment's regimen across infinite possibilities. Here, we report the phase I assessment of a new schedule for metronomic vinorelbine in treating refractory advanced NSCLC and mesothelioma patients. RESULTS: Overall, 13 patients were screened and 12 were treated (50% male, median age: 68yrs), including 9 NSCLC patients. All patients received at least one week (3 doses) of treatment. At data cut-off, the median length of treatment was 6...
May 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28524904/metastatic-lung-cancer-and-distress-use-of-the-distress-thermometer-for-patient-assessment
#3
Victoria Sherry, Carmen Guerra, Anjana Ranganathan, Susan M Schneider
BACKGROUND: Patients with metastatic lung cancer experience high levels of distress related to their disease trajectory and treatment. Oncology nurses are experts in patient care and symptom management, giving them an opportunity to screen and treat patients' distress.
. OBJECTIVES: The objectives of this study were to screen patients for distress and manage their symptoms to positively affect their quality of life, treatment adherence, and clinical outcomes, and to reduce healthcare costs...
June 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28523154/survival-rate-and-prognostic-factors-of-surgically-resected-clinically-synchronous-multiple-primary-non-small-cell-lung-cancer-and-further-differentiation-from-intrapulmonary-metastasis
#4
Fei Xiao, Deruo Liu, Yongqing Guo, Bin Shi, Zhiyi Song, Yanchu Tian, Zhenrong Zhang, Chaoyang Liang
BACKGROUND: The diagnosis, staging, and therapeutic strategy for synchronous multiple primary non-small cell lung cancer (SMP-NSCLC) remain unclear. Distinguishing SMP-NSCLC from intrapulmonary metastasis is difficult but of great importance for selecting the surgical procedure and prognoses. METHODS: Fifty-two patients diagnosed with SMP-NSCLC according to the modified Martini-Melamed criteria in the thoracic surgery department of the China-Japan Friendship Hospital from November 2004 to December 2015 were enrolled in this retrospective study...
April 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28521182/should-nonsmokers-be-excluded-from-early-lung-cancer-screening-with-low-dose-spiral-computed-tomography-community-based-practice-in-shanghai
#5
Xiaoyang Luo, Shanbo Zheng, Quan Liu, Shengping Wang, Yuan Li, Lei Shen, Guodong Li, Wentao Li, Yanping Zhao, Huilin Xu, Jing Wang, Xiaohua Liu, Yunjian Pan, Hong Hu, Yihua Sun, Haiyan Yang, Su Xu, Haiquan Chen
OBJECTIVE: We investigated the efficacy of early lung cancer screening with low-dose spiral computed tomography(LDCT) in both smokers and nonsmokers based on the current situation of community health service, with integration of superior resources of medical institutions at all levels in Shanghai. METHODS: From August 2013 to August 2014, we screened 11,332 (male 7144; female 4188) high-risk individuals in selected communities of Minhang, Shanghai City, for early diagnosis of lung cancer with LDCT combined with multidisciplinary comprehensive treatment pattern including minimally invasive surgery, exploring the medical service network covering prevention, diagnosis, treatment, rehabilitation, and follow-up...
May 15, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28514755/a-novel-serum-based-biomarker-panel-has-complementary-ability-to-preclude-presence-of-early-lung-cancer-for-low-dose-ct-ldct
#6
Xiaobing Wang, Xiuyi Zhi, Zhaogang Yang, Haimei Tian, Yanfen Li, Mo Li, Wenya Zhao, Chao Zhang, Teng Wang, Jing Liu, Di Shen, Cuining Zheng, Dan Zhao, Sheng Yang, Jun Qi, Hongwu Xin, Alexander Stojadinovic, Itzhak Avital, L James Lee, Jianyu Rao, Wei Zhang
Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and mortality rates in high-risk individuals, which was, however, limited by specifically coverage for heavy smokers and high rates of false positivity. Here, we aim to investigate a novel biomarker for early detection of lung cancer, and further extend to concentrate high-risk subjects for increasing specificity and coverage of LDCT. We performed retrospective blinded evaluation of lung cancer and healthy controls in training and validation cohorts...
April 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28512336/lung-cancer-screening-based-on-type-different-sensor-arrays
#7
Wang Li, Hongying Liu, Dandan Xie, Zichun He, Xititan Pi
In recent years, electronic nose (e-nose) systems have become a focus method for diagnosing pulmonary diseases such as lung cancer. However, principles and patterns of sensor responses in traditional e-nose systems are relatively homogeneous. Less study has been focused on type-different sensor arrays. In this paper, we designed a miniature e-nose system using 14 gas sensors of four types and its subsequent analysis of 52 breath samples. To investigate the performance of this system in identifying and distinguishing lung cancer from other respiratory diseases and healthy controls, five feature extraction algorithms and two classifiers were adopted...
May 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28510291/associations-between-rna-splicing-regulatory-variants-of-stemness-related-genes-and-racial-disparities-in-susceptibility-to-prostate-cancer
#8
Yanru Wang, Jennifer A Freedman, Hongliang Liu, Patricia G Moorman, Terry Hyslop, Daniel J George, Norman H Lee, Steven R Patierno, Qingyi Wei
Evidence suggests that cells with a stemness phenotype play a pivotal role in oncogenesis, and prostate cells exhibiting this phenotype have been identified. We used two genome-wide association study (GWAS) datasets of African descendants, from the Multiethnic/Minority Cohort Study of Diet and Cancer (MEC) and the Ghana Prostate Study, as well as two GWAS datasets of non-Hispanic whites, from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and the Breast and Prostate Cancer Cohort Consortium (BPC3), to analyze the associations between genetic variants of stemness-related genes and racial disparities in susceptibility to prostate cancer...
May 16, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28508744/overexpression-of-human-papillomavirus-type-16-oncoproteins-enhances-epithelial-mesenchymal-transition-via-stat3-signaling-pathway-in-non-small-cell-lung-cancer-cells
#9
Wenzhang Zhang, Xin Wu, Liang Hu, Yuefan Ma, Zihan Xiu, Bingyu Huang, Yun Feng, Xudong Tang
Human papillomavirus (HPV) infection may be associated with the development and progression of non-small cell lung cancer (NSCLC). However, the role of HPV-16 oncoproteins in the development and progression of NSCLC is not completely clear. Epithelial-mesenchymal transition (EMT), a crucial step for invasion and metastasis, plays a key role in the development and progression of NSCLC. Here, we explored the effect of HPV-16 oncoproteins on EMT and the underlying mechanisms. NSCLC cell lines, A549 and NCI-H460, were transiently transfected with EGFP-N1-HPV-16 E6 or E7 plasmid...
December 15, 2016: Oncology Research
https://www.readbyqxmd.com/read/28508282/malignancy-incidence-management-and-prevention-in-patients-with-rheumatoid-arthritis
#10
REVIEW
Katelynn M Wilton, Eric L Matteson
Traditional and biologic disease-modifying antirheumatic drugs (DMARDs) are effective medications for the management of rheumatoid arthritis (RA). However, the effects of these medications on immune function raises concern that they may increase long-term cancer risk. The baseline risk for some cancers appears to differ in patients with RA compared to the general population, with the former having an increased risk of lymphoma, lung cancer and renal cancer, but a decreased risk of colorectal and breast cancer...
May 15, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28507311/disruption-of-shh-signaling-cascade-by-sbe-attenuates-lung-cancer-progression-and-sensitizes-ddp-treatment
#11
Jing Du, Weiwei Chen, Lijuan Yang, Juanjuan Dai, Jiwei Guo, Yan Wu, Kaikai Gong, Jian Zhang, Ning Yu, Zhen Xie, Sichuan Xi
Deregulated Sonic Hedgehog (SHH) pathway facilitates the initiation, progression, and metastasis of Non-small cell lung cancer (NSCLC), confers drug resistance and renders a therapeutic interference option to lung cancer patients with poor prognosis. In this study, we screened and evaluated the specificity of a Chinese herb Scutellariabarbata D. Don extraction (SBE) in repressing SHH signaling pathway to block NSCLC progression. Our study confirmed that aberrant activation of the SHH signal pathway conferred more proliferative and invasive phenotypes to human lung cancer cells...
May 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28507205/a-case-of-metastatic-atypical-neuroendocrine-tumor-with-alk-translocation-and-diffuse-brain-metastases
#12
Victoria E Wang, Lauren Young, Siraj Ali, Vincent A Miller, Anatoly Urisman, John Wolfe, Trever G Bivona, Bertil Damato, Shannon Fogh, Emily K Bergsland
A challenge in precision medicine requires identification of actionable driver mutations. Critical to such effort is the deployment of sensitive and well-validated assays for mutation detection. Although identification of such alterations within the tumor tissue remains the gold standard, many advanced non-small cell lung cancer cases have only limited tissue samples, derived from small biopsies or fine-needle aspirates, available for testing. More recently, noninvasive methods using either circulating tumor cells or tumor DNA (ctDNA) have become an alternative method for identifying molecular biomarkers and screening patients eligible for targeted therapies...
May 15, 2017: Oncologist
https://www.readbyqxmd.com/read/28506066/de-novo-computational-design-for-development-of-a-peptide-ligand-oriented-to-vegfr-3-with-high-affinity-and-long-circulation
#13
Hong M Li, Zhi P Dong, Qi Y Wang, Li X Liu, Bing X Li, Xiao N Ma, Ming S Lin, Tao Lu, Yue Wang
The overexpression of VEGFR-3 is correlated with a worse prognosis in lung cancer and has been regarded as a rational target for specific drug delivery. Here, VEGFR-3 homing peptide library was efficiently established by computational design. Strong fluorescent signal of selected peptides were observed in A549 cells, but much weaker in other cells. The positive immunostaining overlapped with VEGFR-3 confirmed high affinity and selectivity of one novel peptide (CP-7). In addition, cell uptake of FITC-CP-7 peptide was significantly blocked by co-injection of excess CP-7 peptide...
May 16, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28504720/a-clinical-drug-library-screen-identifies-clobetasol-propionate-as-an-nrf2-inhibitor-with-potential-therapeutic-efficacy-in-keap1-mutant-lung-cancer
#14
E-J Choi, B-J Jung, S-H Lee, H-S Yoo, E-A Shin, H-J Ko, S Chang, S-Y Kim, S-M Jeon
The Kelch-like ECH-associated protein 1 (KEAP1)-nuclear factor E2-related factor 2 (NRF2)pathway has a central role in cellular antioxidant defense. NRF2 activation due to KEAP1 or NRF2 mutations occurs frequently in many cancers, suggesting that NRF2 inhibition could be a promising therapeutic strategy. However, no potent NRF2 inhibitors are clinically available to date. To develop potent NRF2 inhibitors for therapeutic purpose, we screened ~4000 clinical compounds and determined clobetasol propionate (CP) as the most potent NRF2 inhibitor...
May 15, 2017: Oncogene
https://www.readbyqxmd.com/read/28502721/met-exon-14-skipping-mutations-in-lung-adenocarcinoma-clinicopathologic-implications-and-prognostic-values
#15
Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-Bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
INTRODUCTION: Response to MET inhibitors in non-small cell lung cancer with MET exon 14 (METex14) skipping has fueled molecular screening efforts and search for optimal therapies. However, further work is needed to refine the clinicopathologic and prognostic implications of METex14 skipping METHODS: Among 795 East-Asian patients who underwent surgery for non-small cell lung cancer, we screened 45 patients with quintuple-negative (EGFR-/KRAS-/ALK-/ROS1-/RET-) lung adenocarcinomas using RT-PCR, and found 17 patients (37...
May 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28499861/the-cost-effectiveness-of-high-risk-lung-cancer-screening-and-drivers-of-program-efficiency
#16
Sonya Cressman, Stuart J Peacock, Martin C Tammemagi, William K Evans, Natasha B Leighl, John R Goffin, Alain Tremblay, Geoffrey Liu, Daria Manos, Paul MacEachern, Rick Bhatia, Serge Puksa, Garth Nicholas, Annette McWilliams, John R Mayo, John Yee, John C English, Reka Pataky, Emily McPherson, Sukhinder Atkar-Khattra, Michael R Johnston, Heidi Schmidt, Frances A Shepherd, Kam Soghrati, Kayvan Amjadi, Paul Burrowes, Christian Couture, Harmanjatinder S Sekhon, Kazuhiro Yasufuku, Glenwood Goss, Diana N Ionescu, David M Hwang, Simon Martel, Don D Sin, Wan C Tan, Stefan Urbanski, Zhaolin Xu, Ming-Sound Tsao, Stephen Lam
BACKGROUND: Lung cancer risk prediction models have the potential to make programs more affordable; however, the economic evidence is limited. METHODS: Participants in the National Lung Cancer Screening Trial (NLST) were retrospectively identified with the PLCOm2009 risk-prediction tool. The high-risk subgroup was assessed for lung cancer incidences and demographic character compared with the low-risk subgroup and the Pan-Canadian Early Detection of Lung Cancer Study (PanCan)-an observational study, that was high-risk selected in Canada...
May 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28498428/differential-expression-profiles-of-micrornas-as-potential-biomarkers-for-the-early-diagnosis-of-lung-cancer
#17
Yanqiu Zhang, Jing Sui, Xian Shen, Chengyun Li, Wenzhuo Yao, Weiwei Hong, Hui Peng, Yuepu Pu, Lihong Yin, Geyu Liang
Lung cancer is one of the most lethal malignancies worldwide. To reduce the high morbidity and mortality of the disease, sensitive and specific biomarkers for early detection are urgently needed. Tumor-specific microRNAs (miRNAs) seem to be potential biomarkers for the early diagnosis and treatment of cancer. In this study, the microarray of miRNAs and mRNAs on the same samples was performed and the intersection taken with The Cancer Genome Atlas (TCGA) lung cancer miRNA/RNAseq dataset. Then, miRNA-mRNA regulatory network was constructed to identify miRNA candidates associated with lung cancer through integrating gene expression and miRNA-target prediction...
April 28, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28496005/circulating-plasma-micrornas-as-potential-markers-to-identify-egfr-mutation-status-and-to-monitor-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-treatment-in-patients-with-advanced-non-small-cell-lung-cancer
#18
Lili Qu, Liangliang Li, Xiaofei Zheng, Hanjiang Fu, Chuanhao Tang, Haifeng Qin, Xiaoyan Li, Hong Wang, Jianjie Li, Weixia Wang, Shaoxing Yang, Lin Wang, Guanhua Zhao, Panpan Lv, Yangyang Lei, Min Zhang, Hongjun Gao, Santai Song, Xiaoqing Liu
We aimed to identify a panel of circulating plasma microRNAs that can predict EGFR mutation status and monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer. Microarrays were performed for the preliminary screening of dysregulated microRNAs in 9 EGFR mutation-positive patients versus healthy controls. MiR-107 was upregulated and miR-195 was downregulated in the exon 19 deletion versus wild-type group. The areas under the receiver operating characteristic curves for miR-107, miR-195, and a panel of these 2 microRNAs were 0...
April 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28494110/computerized-detection-of-lung-nodules-through-radiomics
#19
Jingchen Ma, Zien Zhou, Yacheng Ren, Junfeng Xiong, Ling Fu, Qian Wang, Jun Zhao
PURPOSE: Lung cancer is a major cause of cancer deaths, and the 5-year survival rate of stage IV lung cancer patients is only 2%. However, the 5-year survival rate of stage I lung cancer patients significantly increases to 50%. As such, spiral computed tomography (CT) scans are necessary to diagnose high-risk lung cancer patients in early stages. In this study, a computer-aided detection (CAD) system with radiomics was proposed. This system could automatically detect pulmonary nodules and reduce radiologists' workload and human errors...
May 11, 2017: Medical Physics
https://www.readbyqxmd.com/read/28490462/genome-wide-dna-methylation-analysis-reveals-gabbr2-as-a-novel-epigenetic-target-for-egfr-19-deletion-lung-adenocarcinoma-with-induction-erlotinib-treatment
#20
Xiaomin Niu, Fatao Liu, Yi Zhou, Zhen Zhou, Daizhan Zhou, Ting Wang, Ziming Li, Xiangyun Ye, Yongfeng Yu, Xiaoling Weng, Hong Zhang, Junyi Ye, Meilin Liao, Yun Liu, Zhiwei Chen, Shun Lu
Purpose: The last decade has witnessed the rapid development of personalized targeted therapies in lung cancer. It is still unclear whether epigenetic changes are involved in the response to tyrosine kinase inhibitor (TKI) treatment in epidermal growth factor receptor (EGFR) mutated lung cancer. <p>Experimental Design: Methyl-sensitive cut counting sequencing (MSCC) was applied to investigate the methylation changes in paired tissues before and after erlotinib treatment for 42 days with partial response (PR) from stage IIIa (N2) lung adenocarcinoma patients (N=2) with EGFR 19 deletion...
May 10, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
43671
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"